# Rilonacept in Subjects With Cardiac Sarcoidosis

> **NCT06660732** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 60 (estimated)

## Conditions studied

- Cardiac Sarcoidosis

## Interventions

- **DRUG:** Rilonacept

## Key facts

- **NCT ID:** NCT06660732
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-05
- **Primary completion:** 2026-11
- **Final completion:** 2027-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06660732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06660732, "Rilonacept in Subjects With Cardiac Sarcoidosis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06660732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*